Search results
Showing 991 to 1005 of 1490 results for patients and public
In development Reference number: GID-HTE10069 Expected publication date: TBC
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Evidence-based recommendations on automated percutaneous mechanical lumbar discectomy. This involves using an automated device to cut and remove the part of the disc that’s pressing on the nerve.
View recommendations for HTG88Show all sections
Sections for HTG88
Laparoscopic insertion of peritoneal dialysis catheter (HTG133)
Evidence-based recommendations on laparoscopic insertion of peritoneal dialysis catheter. This involves inserting a tube through small cuts (keyhole surgery) in the abdomen to remove waste product from the blood.
View recommendations for HTG133Show all sections
Sections for HTG133
Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.
View recommendations for HTG82Show all sections
Sections for HTG82
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need